Puma Biotechnology Earnings Call Commercial Update May 4, 2023 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or othe ...

Puma Biotechnology Earnings Call Commercial Update March 2, 2023 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These stat ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Dave Rao - Cowen and Company Sahil Kazmi - B. Riley Securities Operator Good afternoon. My name is Diego, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being reco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State o ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Operator Good afternoon. My name is Paul and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Alex, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference ca ...

Puma Biotechnology Earnings Call Commercial Update May 5, 2022 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statem ...

Call Start: 16:30 January 1, 0000 5:10 PM ET Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chairman, President & Chief Executive Officer Jeffrey Ludwig - Chief Commercial Officer Maximo Nougues - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Alex Hammond - Bank of America Operator Good afternoon. My name is Karen, and I will be your c ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President & CEO Jeff Ludwig - Chief Commercial Officer Maximo Nougues - CFO Conference Call Participants Edward White - H.C. Wainwright Carly Kenselaar - Citi Marc Frahm - Cowen Alex Hammond - Bank of America Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timest ...